Recent Advances and Approach Towards Nucleic Acid Delivery System

1.1. Objective
1.2. Executive Summary
1.3. Technical Segmentation

2.1. Nucleic acid used for therapeutics
2.1.1. SiRNA
2.1.1.1. SiRNA – Current academic research
2.1.1.2. SiRNA – Current industrial trend
2.1.1.3. SiRNA – Geographical distribution for SiRNA therapeutics
2.1.1.4. SiRNA – Key diseases targeted using SiRNA therapeutics
2.1.1.5. SiRNA – Delivery agents for SiRNA
2.1.2. miRNA
2.1.2.1. miRNA – Current academic research
2.1.2.2. miRNA – Current industrial trend
2.1.2.3. miRNA – Geographical distribution for miRNA therapeutics
2.1.2.4. miRNA – Key diseases targeted using miRNA therapeutics
2.1.2.5. miRNA – Delivery agents for miRNA
2.1.3. mRNA
2.1.3.1. mRNA – Current academic research
2.1.3.2. mRNA – Current industrial trend
2.1.3.3. mRNA – Geographical distribution for mRNA therapeutics
2.1.3.4. mRNA – Key diseases targeted using mRNA therapeutics
2.1.3.5. mRNA – Delivery agents for mRNA
2.1.4. shRNA
2.1.3.1. shRNA – Current academic research
2.1.3.2. shRNA – Current industrial trend
2.1.3.3. shRNA – Geographical distribution for shRNA therapeutics
2.1.3.4. shRNA – Key diseases targeted using shRNA therapeutics
2.1.3.5. shRNA – Delivery agents for shRNA
2.1.5. gRNA
2.1.3.1. gRNA – Current academic research
2.1.3.2. gRNA – Current industrial trend
2.1.3.3. gRNA – Geographical distribution for gRNA therapeutics
2.1.3.4. gRNA – Key diseases targeted using gRNA therapeutics
2.1.3.5. gRNA – Delivery agents for gRNA
2.1.6. Key players distribution w.r.t type of Nucleic acid
2.1.7. Nucleic acid delivery system: from bench to Clinical trials for different diseases.
2.1.8. Sentiment analysis: Nucleic acid therapy
2.2. Nucleic acid delivery agents
2.2.1. Liposomes as delivery agent
2.2.1.1. Liposomes - Advantages/Disadvantages
2.2.1.2. Liposomes - Key industrial players
2.2.1.3. Liposomes - Key academic players
2.2.1.4. Liposomes – Important innovations
2.2.1.5. Liposomal NA delivery – Diseases targeted
2.2.2. Lipid nanoparticles as delivery agent
2.2.2.1. Lipid nanoparticles - Advantages/Disadvantages
2.2.2.2. Lipid nanoparticles - Key industrial players
2.2.2.3. Lipid nanoparticles - Key academic players
2.2.2.4. Lipid nanoparticles – Important innovations
2.2.2.5. Lipid nanoparticles NA delivery – Diseases targeted
2.2.3. Lipofectamine as delivery agent
2.2.3.1. Lipofectamine - Advantages/Disadvantages
2.2.3.2. Lipofectamine - Key industrial players
2.2.3.3. Lipofectamine - Key academic players
2.2.3.4. Lipofectamine – Important innovations
2.2.3.5. Lipofectamine NA delivery – Diseases targeted
2.2.4. Nanoparticles as delivery agent
2.2.4.1. Nanoparticles - Advantages/Disadvantages
2.2.4.2. Nanoparticles - Key industrial players
2.2.4.3. Nanoparticles - Key academic players
2.2.4.4. Nanoparticles – Important innovation
2.2.4.5. Nanoparticles NA delivery – Diseases targeted
2.2.5. Protein/Peptides as delivery agent
2.2.5.1. Protein/Peptides - Advantages/Disadvantages
2.2.5.2. Key industrial players
2.2.5.3. Key academic players
2.2.5.4. Protein/Peptides – Important innovation
2.2.5.5. Protein/Peptides based NA delivery – Diseases targeted
2.2.6. Other nucleic acid delivery agents
2.2.6.1. Lipoplex as delivery agent
2.2.6.2. Lipidoid as delivery agent
2.2.6.3. Plant virus capsids as delivery agent
2.2.6.4. HPV particle as delivery agent
2.2.6.5. Nanoparticle mimics as delivery agent
2.2.6.6. Dendrimers as delivery agent
2.2.7. Key players focusing on different nucleic acid delivery agents
2.2.8. Available products
2.2.9. Recent advances in nucleic acid delivery agents (viz. cholesterol-based lipid used for mRNA delivery)
2.3. Nucleic acid delivery techniques
2.3.1. Electroporation for Nucleic acid delivery
2.3.1.1. Electroporation - Advantages/Disadvantages
2.3.1.2. Key industrial players
2.3.1.3. Key academic players
2.3.1.4. Electroporation – Important innovation
2.3.1.5. Electroporation based NA delivery – Diseases targeted
2.3.2. Microinjection for Nucleic acid delivery
2.3.2.1. Microinjection - Advantages/Disadvantages
2.3.2.2. Key industrial players
2.3.2.3. Key academic players
2.3.2.4. Microinjection – Important innovation
2.3.2.5. Microinjection based NA delivery – Diseases targeted
2.3.3. Transfection for Nucleic acid delivery
2.3.3.1. Transfection - Advantages/Disadvantages
2.3.3.2. Key industrial players
2.3.3.3. Key academic players
2.3.3.4. Transfection – Important innovation
2.3.3.5. Transfection based NA delivery – Diseases targeted
2.3.4. DAEA-dextran mediated Nucleic acid delivery
2.3.4.1. DAEA-dextran mediate- Advantages/Disadvantages
2.3.4.2. Key industrial players
2.3.4.3. Key academic players
2.3.4.4. DAEA-dextran mediated NA delivery – Important innovation
2.3.4.5. DAEA-dextran mediated NA delivery – Diseases targeted
2.3.5. Key players focusing on different nucleic acid delivery techniques
2.4. Disease targeted for treatment
2.4.1. Cancer treatment using NA delivery
2.4.2. Plant rot treatment using NA delivery
2.4.3. Leaf blight treatment using NA delivery
2.4.4. Bone disorder treatment using NA delivery
2.4.5. Eye disorder treatment using NA delivery
2.4.6. Arthritis treatment using NA delivery
2.4.7. Diabetes treatment using NA delivery
2.4.8. Metabolic disorder treatment using NA delivery
2.4.9. Cardiovascular disease treatment using NA delivery
2.4.10. Immune disease treatment using NA delivery
2.4.11. Others

3.1. Geographically IP filing activity
3.2. IP filing in Asia
3.3. IP filing in rest of world

4.1. Partnership / Collaboration / Licensing objective
4.2. Information of associated companies
4.1. Collaboration between companies
4.2. Collaboration between company and universities
4.1. Licensing activity
4.2. Acquisition in the technology domain

5.1. Market Segmentation based on Nucleic acid therapeutics
5.2. Market Segmentation based on Nucleic acid delivery agents
5.1. Market Segmentation based on Nucleic acid delivery techniques